- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| IMMUCELL Aktie jetzt für 0€ handeln | |||||
| 07.10. | ImmuCell announces preliminary sales results for Q3 | 1 | Seeking Alpha | ||
| 07.10. | ImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025 | 47 | GlobeNewswire (Europe) | PORTLAND, Maine, Oct. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically... ► Artikel lesen | |
| 07.10. | IMMUCELL CORP /DE/ - 8-K, Current Report | 1 | SEC Filings | ||
| 30.09. | IMMUCELL CORP /DE/ - 8-K, Current Report | 1 | SEC Filings | ||
| 29.09. | ImmuCell names Olivier te Boekhorst as new president and CEO | 1 | Investing.com | ||
| 29.09. | ImmuCell Corporation: ImmuCell Announces Selection of its Next President and CEO | 105 | GlobeNewswire (Europe) | PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically... ► Artikel lesen | |
| 25.08. | IMMUCELL CORP /DE/ - 8-K, Current Report | 1 | SEC Filings | ||
| 15.08. | ImmuCell outlines cautious H2 outlook as capacity expansion supports First Defense suite | 4 | Seeking Alpha | ||
| 14.08. | IMMUCELL CORP /DE/ - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | IMMUCELL CORP /DE/ - 8-K, Current Report | 4 | SEC Filings | ||
| 12.08. | ImmuCell Corporation: ImmuCell Announces Bank Debt Refinancing | 2.658 | GlobeNewswire (Europe) | PORTLAND, Maine, Aug. 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically... ► Artikel lesen | |
| 09.07. | ImmuCell reports 18% sales growth in Q2 2025 | 1 | Investing.com | ||
| 09.07. | ImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025 | 198 | GlobeNewswire (Europe) | PORTLAND, Maine, July 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically... ► Artikel lesen | |
| 09.07. | IMMUCELL CORP /DE/ - 8-K, Current Report | 3 | SEC Filings | ||
| 25.06. | IMMUCELL CORP /DE/ - 8-K, Current Report | 1 | SEC Filings | ||
| 25.06. | ImmuCell initiates CEO succession search ahead of planned 2026 retirement | 1 | Seeking Alpha | ||
| 17.06. | IMMUCELL CORP /DE/ - 8-K, Current Report | 1 | SEC Filings | ||
| 05.06. | ImmuCell Corporation: ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders | 1 | GlobeNewswire (USA) | ||
| 14.05. | ImmuCell Q2 2025 slides: sales momentum continues as Re-Tain awaits FDA approval | 1 | Investing.com | ||
| 14.05. | ImmuCell GAAP EPS of $0.16 | 1 | Seeking Alpha |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,054 | -0,59 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| BB BIOTECH | 44,550 | +0,56 % | BB Biotech - Turning milestones into momentum | BB Biotech (BION) delivered strong Q325 results, underpinned by its focus on innovative biotech companies with differentiated clinical pipelines and promising long-term potential. NAV increased 24.0%... ► Artikel lesen | |
| QIAGEN | 40,760 | +0,90 % | Dax lässt nach - Merck und Qiagen gefragt | Frankfurt/Main - Zum Wochenausklang hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 23.958 Punkten berechnet, ein Minus in Höhe von 0,7 Prozent im Vergleich zum Vortagesschluss.... ► Artikel lesen | |
| AMGEN | 259,50 | +0,70 % | Amgen Announces 2025 Fourth Quarter Dividend | THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the... ► Artikel lesen | |
| NOVAVAX | 7,333 | +0,53 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| BIOGEN | 134,65 | +0,52 % | Ihre wichtigsten Termine: Apple, Mastercard, Eli Lilly, Biogen, VW, Wacker Chemie und Lufthansa im Fokus! | © Foto: Jonathan Brady/PA Wire/dpa +++ dpa-Bildfunk Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | |
| ILLUMINA | 107,00 | -0,41 % | Illumina, Inc.: Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025 | Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basis
GAAP operating margin of 21.0% and non-GAAP operating... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 568,00 | +0,39 % | Aktien New York: Rekordrally setzt sich fort - Optimismus bei KI-Aktien | NEW YORK (dpa-AFX) - Die Rekordrally an den US-Börsen hat sich am Dienstag fortgesetzt. "Die KI-Party in New York geht weiter", kommentierte Christine Romar, Head of Europe beim Broker CMC Markets.... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,040 | 0,00 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 31, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| OCUGEN | 1,370 | +1,60 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,110 | +0,09 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,120 | 0,00 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,416 | +0,91 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 21,000 | +0,86 % | A Peek at Sarepta Therapeutics' Future Earnings |
Das Unternehmen IMMUCELL CORPORATION kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,100 (+1,92 %) liegt der Kurs bei 5,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUCELL CORPORATION finden Sie auf Wallstreet Online.